Teva to Sell Generic Viagra in UK, and Move Patent Filing to Switzerland

Teva, the world leader in generic medication will be soon be launching a generic version of Pfizer's Viagra in the UK and Europe.

Pfizer's Viagra patents expired this past week in the UK and parts of Europe, allowing other manufacturers to move in.

In the US, a court ruling has prevented Teva from introducing generic Viagra until at least 2020.

Teva also announced that it will stop filing its patents in Israel, and will now be filing them instead in Switzerland.

The reason for the move are Switzerland's patent related tax laws, and subsequent tax breaks and benefits they will provide Teva.

Teva said that if Israel were to change its tax codes to make them more competitive with other countries, they'd be happy to move the IP registrations back to Israel, according to a report in Globes.